Key facts
- It has raised $43.7M; the latest was Early Stage VC in Sep 2025.
- Notable investors include HSG (Hong Kong), Shunwei Capital, Shenzhen Guozhong Venture Capital Management, Leader Venture Capital, Nantong Zijing Capital — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Huiliao
- ·The full record, as it builds
Funding rounds
No funding rounds for Huiliao are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Huiliao
Developer of nucleic acid drugs intended to bring more mRNA innovative drugs to the clinic to benefit patients. The company specialises in mRNA drug development and production, clinical trial design, and data analysis, providing customers with infectious disease vaccines, tumour vaccines, cell therapy and protein substitution based on mRNA technology.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2021
- Website
- healrna.com/
- Ownership
- Privately Held (backing)
Huiliao doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Huiliao shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Huiliao in its N-PORT filings yet. We sweep new filings monthly.